tbuckley/cabot-search huggingface dataset:
Remote diagnosis of surgical-site infection using a mobile digital intervention: a randomised controlled trial in emergency surgery patients
Authors: Kenneth A. McLean, Katie E. Mountain, Catherine A. Shaw, Thomas M. Drake, Riinu Pius, Stephen R. Knight, Cameron J. Fairfield, Alessandro Sgrò, Matt Bouamrane, William A. Cambridge, Mathew Lyons, Aya Riad, Richard J. E. Skipworth, Stephen J. Wigmore, Mark A. Potter, Ewen M. Harrison, K. Baweja, W. A. Cambridge, V. Chauhan, K. Czyzykowska, M. Edirisooriya, A. Forsyth, B. Fox, J. Fretwell, C. Gent, A. Gherman, L. Green, J. Grewar, S. Heelan, D. Henshall, C. Iiuoma, S. Jayasangaran, C. Johnston, E. Kennedy, D. Kremel, J. Kung, J. Kwong, C. Leavy, J. Liu, S. Mackay, A. MacNamara, S. Mowitt, E. Musenga, N. Ng, Z. H. Ng, S. O’Neill, M. Ramage, J. Reed, A. Riad, C. Scott, V. Sehgal, A. Sgrò, L. Steven, B. Stutchfield, S. Tominey, W. Wilson, M. Wojtowicz, J. Yang
Journal: npj Digital Medicine (2021)

Surgical site infections (SSI) cause substantial morbidity and pose a burden to acute healthcare services after surgery. We aimed to investigate whether a smartphone-delivered wound assessment tool can expedite diagnosis and treatment of SSI after emergency abdominal surgery. This single-blinded randomised control trial (NCT02704897) enroled adult emergency abdominal surgery patients in two tertiary care hospitals. Patients were randomised (1:1) to routine postoperative care or additional access to a smartphone-delivered wound assessment tool for 30-days postoperatively. Patient-reported SSI symptoms and wound photographs were requested on postoperative days 3, 7, and 15. The primary outcome was time-to-diagnosis of SSI (Centers for Disease Control definition). 492 patients were randomised (smartphone intervention: 223; routine care: 269). There was no significant difference in the 30-day SSI rate between trial arms: 21 (9.4%) in smartphone vs 20 (7.4%, p = 0.513) in routine care. Among the smartphone group, 32.3% (n = 72) did not utilise the tool. There was no significant difference in time-to-diagnosis of SSI for patients receiving the intervention (-2.5 days, 95% CI: -6.6-1.6, p = 0.225). However, patients in the smartphone group had 3.7-times higher odds of diagnosis within 7 postoperative days (95% CI: 1.02-13.51, p = 0.043). The smartphone group had significantly reduced community care attendance (OR: 0.57, 95% CI: 0.34-0.94, p = 0.030), similar hospital attendance (OR: 0.76, 95% CI: 0.28-1.96, p = 0.577), and significantly better experiences in accessing care (OR: 2.02, 95% CI: 1.17-3.53, p = 0.013). Smartphone-delivered wound follow-up is feasible following emergency abdominal surgery. This can facilitate triage to the appropriate level of assessment required, allowing earlier postoperative diagnosis of SSI.
The Beginning of the End of Allogeneic Transplantation for Hurler Syndrome?
Authors: Sandhya Kharbanda, Christopher C. Dvorak
Journal: New England Journal of Medicine (2021)

Hurler syndrome (mucopolysaccharidosis type I, Hurler variant [MPSIH]) is caused by autosomal recessive mutations in IDUA, leading to absent α-L-iduronidase (IDUA) expression. Deficient clearance of glycosaminoglycans (GAGs) leads to profound systemic manifestations, including neurocognitive impairment. IDUA can be endocytosed from the blood, and enzyme-replacement therapy is available. However, the enzyme does not cross the blood–brain barrier, and it is therefore only a bridge to definitive treatment, which is best done at as young an age as possible (preferably <12 months and certainly <18 months).1,2 Until now, definitive treatment has been allogeneic hematopoietic-cell transplantation (HCT), because bone marrow–derived monocytes can migrate . . .
Updated Efficacy of Eltanexor Monotherapy in Patients with Higher Risk Hypomethylating Myelodysplastic Syndrome Primary Refractory to Hypomethylating Agents
Authors: Sangmin Lee, Sanjay R Mohan, Jessica Knupp, Kamal Chamoun, Igor Karasik, Vicky Xiang Bai, Kimberly Ingalls, Fan Yang, Jatin J. Shah, Michael G. Kauffman, Sharon Shacham, Bhavana Bhatnagar
Journal: Blood (2021)
Abstract 9517: Under-Utilization of Conventional Guideline-Directed Medical Therapy Among Patients Eligible for the Recent Large-Scale Clinical Trials of Heart Failure With Reduced Ejection Fraction
Authors: Satoshi Shoji, Shun Kohsaka, Yasuyuki Shiraishi, Mitsuaki Sawano, Nobuhiro Ikemura, Nozomi Niimi, Takashi Kohno, Ayumi Goda, Yuji Nagatomo, Mike Saji, Makoto Takei, Shintaro Nakano, Keiichi Fukuda, Tsutomu Yoshikawa
Journal: Circulation (2021)

Introduction: Recent large-scale clinical trials of novel heart failure (HF) agents (angiotensin receptor-neprilysin inhibitor, sodium-glucose cotransporter 2 inhibitor, and ivabradine) emphasize the use of baseline conventional guideline-directed medical therapy (GDMT; angiotensin-converting enzyme inhibitor, beta-blocker and mineral corticosteroid receptor antagonist); however, its use among real-world trial-eligible patients remains unclear. Objectives: To evaluate the prescription rate of GDMT and its association with long-term outcomes in patients that met enrollment criteria of recent large-scale clinical trials within hospitalized HF patients. Methods: We examined 1631 consecutive patients with HF with reduced ejection fraction (HFrEF) discharged after an episode of acute heart failure in the multicenter registry in Japan. We assessed the use of GDMT among patients that met PARADIGM-HF/ DAPA-HF enrollment criteria and SHIFT enrollment criteria. We then examined the association between the use of GDMT and long-term outcomes within each enrollment criteria. Results: Overall, 63.2% (n=1030) and 34.9% (n=569) of the patients met the enrollments criteria of PARADIGM/DAPA-HF and SHIFT trials. Within each patient subset, 32.5% (n=335) and 29.2% (n=166) had full GDMT, respectively. Although 82.6% (n=470) of patients that met SHIFT enrollment criteria received beta-blockers, only 21.3% (n=121) and 4.4% (n=25) patients were on &gt;50% or higher dose (recommended dose). The use of GDMT was associated with lower rates of 2-year mortality and HF readmission in both of these populations (HR 0.85, 95% CI 0.81-0.89; HR 0.90, 95% CI 0.85-0.95, respectively). Conclusions: The underutilization of GDMT was observed among patients meeting the enrollment criteria of novel trials within Japanese multicenter registry of HF patients. Further effort to optimize the conventional GDMT before initiating novel therapeutics needs to be implemented.
Purine Analogues Increase the Risk of Lethal and/or Prolonged COVID19 While Obinutuzumab Increases the Risk of Prolonged but Not Lethal Infection in Patients Treated for Lymphoid Malignancies -a Study of Krohem, the Croatian Group for Hematologic Diseases
Authors: Igor Aurer, Ozren Jaksic, Sandra Bašić-Kinda, Stefan Mrdenovic, Slobodanka Ostojic Kolonic, Dominik Lozic, Hrvoje Holik, Sabina Novakovic Coha, Petra Bernes, Ivan Krecak, Martina Moric Peric, Marino Narancic, Zdravko Mitrovic, Toni Valkovic
Journal: Blood (2021)
The Genotype of CYP2D6 Determines Cardiac Responsiveness to β-adrenergic Stimulation in patients Treated with Metoprolol, but not with Bisoprolol
Authors: Nozawa T, Taguchi M, Hashimoto Y, Nonomura M, Igarashi N, Igawa A, Matsuki A, Nakadate T, Asanoi H
Journal: Circulation (2005)
Abstract PO-026: CircMYOF acts as a miR-4739 sponge to promote progression and facilitate glycolysis via VEGFA/PI3K/AKT pathway in pancreatic ductal adenocarcinoma
Authors: Dandan Zheng, Xianxian Huang, Juanfei Peng, Yanyan Zhuang, Yuanhua Li, Junchi Qu, Shineng Zhang, Fengting Huang
Journal: Cancer Research (2021)

Abstract Emerging evidences has revealed that circular RNAs (circRNAs) participate in the initiation and development of pancreatic ductal adenocarcinoma (PDAC), a deadly malignancy with extremely low 5-year survival rate. Reprogrammed glucose metabolism is a key feature of tumor development, including PDAC. In this study, we aimed to investigate the role of circRNAs in reprogrammed glucose metabolism in PDAC. RNA sequencing under various glucose incubation circumstance was performed. A new circMYOF was identified. Sanger sequencing and RNase R treatment confirmed its circular RNA characteristics. Real time PCR indicated that it was overexpressed in PDAC tissues and cell lines. Gain-of and loss-of function assay implied that circMYOF promoted progression in PDAC. Mechanically, RNA pull down and luciferase reporter assay suggested that circMYOF, exhibiting as a competing endogenous RNA (ceRNA) for miR-4739, facilitated glycolysis via VEGFA/PI3K/AKT pathway. Taken together, our finding indicates that circMYOF may be a potential biomarker and therapeutic target for PDAC patients. Citation Format: Dandan Zheng, Xianxian Huang, Juanfei Peng, Yanyan Zhuang, Yuanhua Li, Junchi Qu, Shineng Zhang, Fengting Huang. CircMYOF acts as a miR-4739 sponge to promote progression and facilitate glycolysis via VEGFA/PI3K/AKT pathway in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-026.
Anti–Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema
Authors: Mathilde Leclercq, Anaïs Andrillon, Georgina Maalouf, Pascal Sève, Philip Bielefeld, Julie Gueudry, Thomas Sené, Thomas Moulinet, Bénédicte Rouvière, Damien Sène, Anne-Claire Desbois, Fanny Domont, Sara Touhami, Carolla El Chamieh, Patrice Cacoub, Bahram Bodaghi, Lucie Biard, David Saadoun
Journal: Ophthalmology (2021)
Clonal Evolution in a Murine CALM-AF10 Leukemia: Evidence of Functional Heterogeneity of Leukemia Stem Cells
Authors: Niloofar Zandvakili, Hui Mei Lee, Rhea Desai, Alyona Oryshchuk, Peter J. Browett, Purvi M Kakadia, Stefan K. Bohlander
Journal: Blood (2021)
Hospital Pharmacological Treatment of Acute Myocardial Infarction with st Supra: Sus x Private
Authors: Jussiely Oliveira
Journal: Clinical Cardiology and Cardiovascular Interventions (2021)

Objectives: To compare the adequacy of drug therapy in STEMI in public and private hospitals. Methods: Prospective analysis of 471 patients admitted with STEMI in public and private hospitals in the state of Sergipe. Results: Clopidogrel usage fee (91% vs 36% ; p &lt; 0.001 ) and ACE inhibitors (66% vs 22 %; p &lt; 0.001 ) was higher among SUS patients, however, use of ticagrelor (61% vs 1% ; p &lt; 0.001 ) and BRA II (24% vs 9 %, p = 0.002 ) was higher among those treated in the private sector. In the pooled analysis, SUS patients received more IECA and/or BRA II than those with indication an absolute for its use (76% vs 30%; p &lt; 0.001). Conclusions: A significant difference was observed in the use of ACE inhibitors and/or ARBs among patients in both groups, a higher rate of use of these drugs was showed amongst SUS patients.
Salinomycin as a potent anticancer stem cell agent: State of the art and future directions
Authors: Dan Qi, Yunyi Liu, Juan Li, Jason H. Huang, Xiaoxiao Hu, Erxi Wu
Journal: Medicinal Research Reviews (2021)

Abstract Cancer stem cells (CSCs) are a small subpopulation of cells within a tumor that can both self‐renew and differentiate into other cell types forming the heterogeneous tumor bulk. Since CSCs are involved in all aspects of cancer development, including tumor initiation, cell proliferation, metastatic dissemination, therapy resistance, and recurrence, they have emerged as attractive targets for cancer treatment and management. Salinomycin, a widely used antibiotic in poultry farming, was identified by the Weinberg group as a potent anti‐CSC agent in 2009. As a polyether ionophore, salinomycin exerts broad‐spectrum activities, including the important anti‐CSC function. Studies on the mechanism of action of salinomycin against cancer have been continuously and rapidly published since then. Thus, it is imperative for us to update its literature of recent research findings in this area. We here summarize the notable work reported on salinomycin's anticancer activities, intracellular binding target(s), effects on tumor microenvironment, safety, derivatives, and tumor‐specific drug delivery; after that we also discuss the translational potential of salinomycin toward clinical application based on current multifaceted understandings.
Hospital-acquired infections caused by enterococci: a systematic review and meta-analysis, WHO European Region, 1 January 2010 to 4 February 2020
Authors: Simon Brinkwirth, Olaniyi Ayobami, Tim Eckmanns, Robby Markwart
Journal: Eurosurveillance (2021)

Background Hospital-acquired infections (HAI) caused by Enterococcus spp., especially vancomycin-resistant Enterococcus spp. (VRE), are of rising concern. Aim We summarised data on incidence, mortality and proportion of HAI caused by enterococci in the World Health Organization European Region. Methods We searched Medline and Embase for articles published between 1 January 2010 and 4 February 2020. Random-effects meta-analyses were performed to obtain pooled estimates. Results We included 75 studies. Enterococcus spp. and VRE accounted for 10.9% (95% confidence interval (CI): 8.7–13.4; range: 6.1–17.5) and 1.1% (95% CI: 0.21–2.7; range: 0.39–2.0) of all pathogens isolated from patients with HAI. Hospital wide, the pooled incidence of HAI caused by Enterococcus spp. ranged between 0.7 and 24.8 cases per 1,000 patients (pooled estimate: 6.9; 95% CI: 0.76–19.0). In intensive care units (ICU), pooled incidence of HAI caused by Enterococcus spp. and VRE was 9.6 (95% CI: 6.3–13.5; range: 0.39–36.0) and 2.6 (95% CI: 0.53–5.8; range: 0–9.7). Hospital wide, the pooled vancomycin resistance proportion among Enterococcus spp. HAI isolates was 7.3% (95% CI: 1.5–16.3; range: 2.6–11.5). In ICU, this proportion was 11.5% (95% CI: 4.7–20.1; range: 0–40.0). Among patients with hospital-acquired bloodstream infections with Enterococcus spp., pooled all-cause mortality was 21.9% (95% CI: 15.7–28.9; range: 14.3–32.3); whereas all-cause mortality attributable to VRE was 33.5% (95% CI: 13.0–57.3; range: 14.3–41.3). Conclusions Infections caused by Enterococcus spp. are frequently identified among hospital patients and associated with high mortality.
Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults
Authors: Ciaran N. Kohli-Lynch, Brandon K. Bellows, Yiyi Zhang, Bonnie Spring, Dhruv S. Kazi, Mark J. Pletcher, Eric Vittinghoff, Norrina B. Allen, Andrew E. Moran
Journal: Journal of the American College of Cardiology (2021)
Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain
Authors: Hans-Ulrich Klein, Caroline Trumpff, Hyun-Sik Yang, Annie J. Lee, Martin Picard, David A. Bennett, Philip L. De Jager
Journal: Molecular Neurodegeneration (2021)

Abstract Background Mitochondrial dysfunction is a feature of neurodegenerative diseases, including Alzheimer’s disease (AD). Changes in the mitochondrial DNA copy number (mtDNAcn) and increased mitochondrial DNA mutation burden have both been associated with neurodegenerative diseases and cognitive decline. This study aims to systematically identify which common brain pathologies in the aged human brain are associated with mitochondrial recalibrations and to disentangle the relationship between these pathologies, mtDNAcn, mtDNA heteroplasmy, aging, neuronal loss, and cognitive function. Methods Whole-genome sequencing data from n = 1361 human brain samples from 5 different regions were used to quantify mtDNAcn as well as heteroplasmic mtDNA point mutations and small indels. Brain samples were assessed for 10 common pathologies. Annual cognitive test results were used to assess cognitive function proximal to death. For a subset of samples, neuronal proportions were estimated from RNA-seq profiles, and mass spectrometry was used to quantify the mitochondrial protein content of the tissue. Results mtDNAcn was 7–14% lower in AD relative to control participants. When accounting for all 10 common neuropathologies, only tau was significantly associated with lower mtDNAcn in the dorsolateral prefrontal cortex. In the posterior cingulate cortex, TDP-43 pathology demonstrated a distinct association with mtDNAcn. No changes were observed in the cerebellum, which is affected late by pathologies. Neither age nor gender was associated with mtDNAcn in the studied brain regions when adjusting for pathologies. Mitochondrial content and mtDNAcn independently explained variance in cognitive function unaccounted by pathologies, implicating complex mitochondrial recalibrations in cognitive decline. In contrast, mtDNA heteroplasmy levels increased by 1.5% per year of life in the cortical regions, but displayed no association with any of the pathologies or cognitive function. Conclusions We studied mtDNA quantity and quality in relation to mixed pathologies of aging and showed that tau and not amyloid-β is primarily associated with reduced mtDNAcn. In the posterior cingulate cortex, the association of TDP-43 with low mtDNAcn points to a vulnerability of this region in limbic-predominant age-related TDP-43 encephalopathy. While we found low mtDNAcn in brain regions affected by pathologies, the absence of associations with mtDNA heteroplasmy burden indicates that mtDNA point mutations and small indels are unlikely to be involved in the pathogenesis of late-onset neurodegenerative diseases.
Abstract 9389: Apache Clinical Text Analysis Knowledge Extraction System (ctakes) Identifies One Out of Five Suspicious Symptoms of Acute Coronary Syndrome from Emergency Department Nursing Triage Notes
Authors: Stephanie O Frisch, Denis Newman-Griffis, Zhendong Wang, Jessica K Zegre-hemsey, Clifton W CALLAWAY, Harry Hochheiser, Holli A Devon, Suzanne Bakken, Ervin Sejdic
Journal: Circulation (2021)

Introduction: Acute coronary syndrome is a time sensitive condition requiring rapid identification, but nurses only identify 40%-50% of high-risk patients at emergency department (ED) triage. Symptoms are the driving force behind prompt ED care of patients with ACS. Symptom data are recorded as free text in nursing narratives. Standardized extraction of symptoms via natural language processing will create usable clinical data that could be used in predictive analytics, to improve early identification of ACS and ensure life-saving treatments. Hypothesis: The Apache Clinical Text Analysis and Knowledge Extraction System (cTAKES) will recognize symptom concepts in nursing narratives with an acceptable F1 score of greater than or equal to 0.9. Methods: A nurse scientist and a physician annotated 1200 ED nursing narratives of patients with suspicion of ACS for the following symptoms predictive of ACS: chest pain, chest discomfort, shortness of breath, fatigue and sweating. Inter-rater reliability (Cohen’s kappa statistic) was calculated with 10% overlap. cTAKES, which is an open-source natural language processing platform, was applied to extract evidence of the 5 annotated symptoms. Recall (sensitivity), precision (positive predictive value) and F1 score (harmonic mean of precision and recall) were calculated to assess extraction quality for each symptom. Results: Recall, precision and F1 score for each symptom are as follows: chest pain: 0.71, 0.97, 0.823; chest discomfort: 0.6, 0.9, 0.72; fatigue: 0.9, 0.26, 0.41; shortness of breath: 0.93, 0.96, 0.95; and sweating: 0.54, 1, 0.7, respectively. Cohen’s kappa was 0.9. Conclusions: cTAKES had fair results across all 5 ACS predictive symptoms, with shortness of breath meeting our hypothesized F1 score goal. Failure to recognize symptoms at a clinically acceptable value might be due to the linguistic and content variation present in ED nursing initial narratives. Customized natural language processing pipelines trained specifically for ED nursing narratives have significant potential for accurately identifying symptoms and improving early identification of ACS.
Terraflow, a New High Parameter Data Analysis Tool, Reveals Systemic T-Cell Exhaustion and Dysfunctional Cytokine Production in Classical Hodgkin Lymphoma
Authors: Dan Freeman, Linda Lam, Tri Li, Jason Alexandre, Bruce G. Raphael, David Kaminetzky, Jia Ruan, Pratip Chattopadhyay, Catherine S. Diefenbach
Journal: Blood (2021)
Identification of Complement-Related Missense Variants in Pediatric Patients with Acute and Post COVID-19 Syndromes
Authors: Eleni Gavriilaki, Tasoula Touloumenidou, Stefanos Tsiftsoglou, Athanasios Tragiannidis, Evangelia Farmaki, Paraskevi Panagopoulou, Elisavet Michailidou, Evdoxia Koravou, Maria Koutra, Ilias Iosifidis, Eleni Papadimitriou, Efimia Papadopoulou-Alataki, Penelope Georgia Papayanni, Christos Varelas, Apostolia Papalexandri, Athanasios Evangeliou, Assimina Galli-Tsinopoulou, Dimitrios Zafeiriou, Emmanuel Roilides, Ioanna Sakellari, Achilles Anagnostopoulos
Journal: Blood (2021)
Lenalidomide and Eltrombopag for Treatment in Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Study Combination Clinical Trial
Authors: Jesus D Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William Donnellan, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammad Kazemi, Ioannis Mantzaris, R. Alejandro Sica, Lizamarie Bachier-Rodriguez, Mendel Goldfinger, Noah Kornblum, Kira Gritsman, Ira Braunschweig, Ulrich G. Steidl, Britta Will, Aditi Shastri, Amit Verma
Journal: Blood (2021)
Clinical Risk Factors and Prognostic Model for Idiopathic Inflammatory Demyelinating Diseases after Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies
Authors: Rui-Xin Deng, Yun He, Xiao-Lu Zhu, Hai-Xia Fu, Xiao-Dong Mo, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Hui Zhang
Journal: Blood (2021)
A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Shaji Kumar, Anita D'Souza, Nina Shah, Cesar Rodriguez, Peter M. Voorhees, Orlando F. Bueno, Ben Buelow, Kevin J. Freise, Susan Yue, Rajvineeth Kumar Pothacamury, Akshanth R. Polepally, Ravi Vij
Journal: Blood (2021)
Late Onset and Long Lasting Idiopathic and Autoimmune Neutropenia As Epiphenomena of Immune Dysregulation: Preliminary Data Study from the Italian Neutropenia Registry
Authors: Francesca Fioredda, Francesca Fioredda, Marina Lanciotti, Cecilia Contratto, Giovanni Del Borrello, Michela Lupia, Paola Terranova, Eleonora Rotondo, Domenico Coviello, Maurizio Miano, Antonio Marzollo, Adele Civino, Francesca Bagnasco, Alice Grossi, Andrea Beccaria, Carlo Dufour
Journal: Blood (2021)
Review of Unrelated Donor Cord Blood Transplantation in Children over the Past 3 Decades
Authors: Joanne Kurtzberg, Jesse D Troy, Kristin M. Page, Hanadi Rafii-Elayoubi, Fernanda Volt, Graziana Maria Scigliuolo, Barbara Cappelli, Vanderson Rocha, Annalisa Ruggeri, Eliane Gluckman
Journal: Blood (2021)
Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study
Authors: Gail J. Roboz, Thomas Pabst, Ahmed Aribi, Joseph M. Brandwein, Hartmut Döhner, Walter Fiedler, Domenica Gandini, Michelle Geddes, Jing-Zhou Hou, Angela J. Howes, Anna Hultberg, Eric Huselton, Julie Jacobs, Colleen Kane, Ewa Lech-Marańda, Marieke Louwers, Kerri Nottage, Uwe Platzbecker, Raajit Rampal, Mariya Salman, Priya Shah, Don Stevens, Monic Stuart, Marion Subklewe, Anne Sumbul, Eunice S. Wang, Agnieszka Wierzbowska, Bin Yao, Karen Yee, Hagop Kantarjian, Gautam Borthakur
Journal: Blood (2021)